Clinical Studies

Backed by science. Proven over time.

Efficacy demonstrated in two studies, radiolabeled and clinical field trial.¹ Prescribed for over 25 years (includes U.S. approval) to help control signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Inhibits enzymes that break down cartilage, so joint damage is reduced.¹

Clinical field trial demonstrated key improvements.

Assessed lameness, range of motion, pain and functional disability.¹
Dogs treated with Adequan® Canine (polysulfated glycosaminoglycan) showed a statistically significant improvement in range of motion and total orthopedic score over placebo-treated control dogs.¹

Percent improvement¹

Patients treated with Adequan^® Canine showed greater improvement than dogs given a placebo.

Adequan^® Canine patients had better range of motion scores (p = 0.007) and total orthopedic scores (p = 0.025) at the end of treatment than at the beginning of the study.

Improved Range of Motion

(Controlled Field Trial - 51 Dogs)

Adequan Canine treatment improvement results

Adequan^® Canine Polysulfated Glycosaminoglycan Sterile Injection 100 mg/mL

INDICATIONS Adequan^® Canine is recommended for the treatment of non-infectious degenerative and/or traumatic arthritis and associated lameness of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan^® Canine is for veterinary use only. The prescribing information contains complete use information which includes dosing, contraindications, warnings and cautions. Always read, understand and follow label and use directions. PLEASE CONSULT the Full Prescribing Information.

1. Data on File.